| Glucagon‐like peptide‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches? A Kobayati, A Haidar, MA Tsoukas Diabetes, Obesity and Metabolism 24 (5), 769-787, 2022 | 18 | 2022 |
| Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in adults with suboptimally controlled type 1 diabetes: a randomized crossover controlled trial MR Pasqua, A Jafar, A Kobayati, MA Tsoukas, A Haidar Diabetes Care 46 (1), 165-172, 2023 | 10 | 2023 |
| 176-OR: The effect of low-dose empagliflozin on glucose control in suboptimally controlled adults with type 1 diabetes on a closed-loop insulin delivery system MR Pasqua, A Jafar, A Kobayati, M Tsoukas, A Haidar Diabetes 71 (Supplement_1), 2022 | 1 | 2022 |
| 79-OR: A Novel Decision Support System for Automated Adaptations of Insulin Injections in Type 1 Diabetes—A Randomized Controlled Trial A KOBAYATI, A EL FATHI, N GARFIELD, L LEGAULT, JF YALE, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| LOW-DOSE EMPAGLIFLOZIN AS ADJUNCT TO HYBRID CLOSED-LOOP INSULIN THERAPY IN SUB-OPTIMALLY CONTROLLED ADULTS WITH TYPE 1 DIABETES: A RANDOMIZED CROSSOVER CONTROLLED TRIAL M Pasqua, A Jafar, A Kobayati, M Odabassian, M Tsoukas, A Haidar Canadian Journal of Diabetes 47 (7), S120, 2023 | | 2023 |
Ahmad HaidarMcGill University在 mail.mcgill.ca 的电子邮件经过验证
Ahmad HaidarMcGill University在 mail.mcgill.ca 的电子邮件经过验证